Resources
BNET Business Dictionary
- Sales
- the activity of selling a company's products or services, the income generated by this, or the department that deals with selling
- Sales definition on BNET »
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Andrx Corporation Reports Financial Results for 2006 First Quarter
- FORT LAUDERDALE, Fla. -- Andrx Corporation (Nasdaq:ADRX) ("Andrx" or the "Company") today announced its financial results for the three months ended March 31, 2006 (the "2006 Quarter"), which are discussed more extensively in Andrx's Form 10-Q for the 2006 Quarter ("March 2006 10-Q") being filed today with the U.S. Securities...
- Research articles 2006-05-04
- BASF Outlines Growth Strategy In Major Markets.
- The company will focus on health and nutrition following acquisitions. BASF POSTED record sales during its fiscal second quarter, mainly because of the strong performance of its cyclical and commodity products. But because of a refocusing of ...
- Research articles 2000-08-14
- Comparative Analysis 2000. Top 100 Global Chemical Companies.(sales and employees)(Illustration)(Statistical Data Included)
- Comparative Analysis 2000. Top 100 Global Chemical Companies All in $m except employees. ...
- Research articles 2001-10-15
Additional Resources
- Takeda May Divest Latex Operations.(Takeda Chemical Industries Ltd.)(International Pages)(Brief Article)
- Takeda Chemical Osaka is considering selling its [yen]2.8-billion($22 million)/year styrene-butadiene SB latex business to Nippon A&L, a 67-33 joint venture between Sumitomo Chemical and Mitsui Chemicals. Takeda transferred sales and marketing responsibility for its SB latex operation to Nippon A&L on July 1. Takeda operates ...
- Research articles 2001-07-04
- Sumitomo JV to buy Takeda's SB latex. (News Briefs).(joint venture; Nippon A and L Inc., Takeda Chemical Industries Ltd.)(Brief Article)
- Nippon A&L Osaka, a 67-33 joint venture between Sumitomo Chemical and Mitsui Chemicals, has agreed to acquire Takeda Chemical Industries styrene butadiene SB latex business, effective October 1, for an undisclosed amount. The business makes SB latex at Shimizu, Japan and has sales of [en]2.5 billion($22...
- Research articles 2002-08-07
- Mitsui Chemicals, Takeda Merge Polyurethanes.(Takeda Chemical Industries)(Brief Article)
- Mitsui Chemicals and Takeda Chemical Industries have agreed to merge their respective polyurethane PU raw material businesses into a 51-49 joint venture, Mitsui Takeda Chemicals MTC. The merged company will begin operating next April, subject to antitrust approval. MTC will be Asia's biggest PU raw material...
- Research articles 2000-10-04
- Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates
- Amgen to Receive $200 Million Upfront Payment, $702 Million in Multi-year Global R&D Expense Sharing and Success-based Milestones, and Double Digit Royalties on Japan Sales; Takeda Will Receive Exclusive Rights to Develop and Commercialize Select Molecules in Japan
- Research articles 2008-02-04
- Abbott under kickback probe over Depakote sales -
- Abbott Laboratories this morning confirmed the company's sales and marketing practices of Depakote, the widely used drug to treat bipolar disorder and epilepsy, are under federal investigation. The U.S. Department of Justice , through the U.S. Attorney for the Western District of Virginia...
- News items 2009-11-06
- And the World's Worst Product Is...
- ...sleeping pills advertised to children (although they may look appealing when the kids are all pumped-up on sugar later tonight.) Consumers International, a global consumer group, accepted submissions from consumer organizations around the world, and formulated an abridged list of bad products based on the following criteria: the size of the company,...
- Blog posts 2007-10-31
- Pfizer Gains Presence in Diabetes Market with Takeda Deal
- ChinaBio Today submits: Pfizer (NYSE: PFE) has taken on the job of co-promoting a diabetes drug in China for Takeda Pharmaceutical Company. Actos pioglitazone HCl, an oral treatment for diabetes 2, produces over $4 billion of annual revenues for Takeda worldwide. The agreement will be in force until 2020...
- External links 2009-12-16
- Sales for the pharmaceutical company Takeda increased by 7% to reach 935,213 million.
- M2 PRESSWIRE-31 May 2006-Research and Markets: Sales for the pharmaceutical company Takeda increased by 7 to reach 935,213 million.C1994-2006 M2 COMMUNICATIONS LTD RDATE:02062006 Dublin: Research and Markets (http://www.researchandmarkets.com/reports/c37826) has announced the addition of the Espicom Business Intelligence Ltd report: Takeda...
- Research articles 2006-05-31
- Cephalon Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions We will take our first question from David Buck with Buckingham Research. David Buck - Buckingham Research Hi, yes. Thanks for taking my question. Just three quick questions. First for Frank or Kevin, what precipitated the reserve and the timing of the...
- Earnings calls 2007-07-31
- Insomnia Pill Makers Go After Elderly With New 'Fear of Falling'
- For years, drug companies have tried to expand the range of prescriptions of sleeping pills. They're not just for sleeping any more -- now they're also for avoiding "rebound insomnia" in the elderly, "increased risk of automotive crashes, decreased work performance ... or mood changes," generalized anxiety disorder, and depression....
- Blog posts 2008-09-11
- Dendrite Announces Record Time Rollout With Takeda; Japan's Largest Pharmaceutical Company Implements Sales Force Effectiveness Solution for 2,000 Users in 7 Months
- MORRISTOWN, N.J.--BUSINESS WIRE--August 24, 1998--Dendrite International, Inc. (NASDAQ/NMS:DRTE), today announced the highly successful rollout of 2,000 users at Takeda Chemical Industries Ltd. last month. This rollout including customization, pilot and full user training was fully completed within 7 months of the signing. This is recognized to be both a Japanese...
- Research articles 1998-08-24
- Insomnia and Antidepressant Sales Give Lie to DTC Myths
- Direct-to-consumer drug advertising has almost no relationship with consumer demand for prescriptions. That is one interpretation of a story in Ad Age showing that scrips for insomnia pills (such as Sanofi-Aventis's Ambien CR) and antidepressants (such as Eli Lilly's Cymbalta) are up, even though advertising in both those categories is...
- Blog posts 2009-03-05
- Japan rule on stockholdings could be a boon to investors.
- Feb 28, 2003 (The Asian Wall Street Journal - ABIX via COMTEX) Japanese banks and companies will be forced by regulatory changes to reduce their shareholdings. Investors with a long-term investment strategy can benefit handsomely from these forced sales. Masatoshi Sato, a stock-market strategist...
- Research articles 2003-02-28
- Fraud Trial of Officials at Illinois-Based Drug Sales Firm Begins.
- By Alice Dembner, The Boston Globe Knight Ridder/Tribune Business News Apr. 20--In a case that challenges longstanding marketing tactics of the drug industry, eleven current and former officials of TAP Pharmaceutical Products go on trial today for allegedly defrauding the government...
- Research articles 2004-04-20
- DotW: Sesame Street
- In case you failed to run a Google search this week, you may not have realized that on Tuesday Nov. 10, Sesame Street turns 40. You gotta admit, the show doesn't look a day over five--and that's without Botox.If you've forgotten how to get to Sesame Street, we have a...
- News items 2009-11-06
- Sucampo Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Our first question is coming from the line of Ian Sanderson with Cowen and Company. Please proceed with your question. Ian Sanderson - Cowen and Company Thank you and good morning. Thanks for taking the question. Mariam, can you provide some additional color on Takeda's...
- Earnings calls 2008-05-26
- Sucampo Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of Jim Molloy with Caris & Company. Please proceed. Jim Molloy - Caris & Company $15 million was the topline number from Takeda for Amitiza. Is that correct? Jan Smilek That is correct. Jim Molloy - Caris &...
- Earnings calls 2009-05-08
- << Previous
- page 1 of 1
- Next >>
Presented by American Express